Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. | With GSK kicking its R&D engine into high gear in ...

Archer’s Midnight aircraft nears production, targeting FAA approval by 2025 for passenger flights. Click here to read my most recent analysis of ACHR.

Advanced Micro-Fabrication Equipment Inc., China (AMEC) has delivered the world's first Primo Menova 12-inch metal etching system to a top domestic IC design and manufacturing service provider ...

UK unveils 'modern industrial strategy' to boost growth, innovation and investment; critics say it overlooks large parts of the economy.

To improve firms’ enthusiasm for R&D investment, governments worldwide have implemented a series of tax incentives, such as the Super Tax Deduction policy (STD-policy), and the Preferential Income Tax ...

Sigachi Industries, a Hyderabad-based small-cap pharmaceutical firm, saw a near 2 per cent rise in its share price on 18 June 2025 after unveiling a strategic R&D centre aimed at accelerating API ...

Can Strategy Actually Pay These Shareholders? Ultimately, the investment case for any of these preferred stock shares lies in the ability Strategy has to actually pay shareholders back.

Micron Technology Inc. will spend about $200 billion on US manufacturing, research and development, including $150 billion for domestic manufacturing capacity and $50 billion for R&D. The company ...

Government R&D encompasses all innovative work the government directly pays for, regardless of who does it.